Pandemic Response Strains Global Biopharmaceutical Reactor Capacity
Executive Summary
Distress grows as manufacturers wait for suppliers to boost production. One idea: stretch inventories by qualifying single-use bioreactors for reuse.
You may also be interested in...
How Biotech Firms Kept Raw Material Shortages From Affecting Patients During Pandemic
Biogen, Amgen, Lilly and Genentech experts shared tales of impending stockouts, particularly for single-use assemblies, filters and resins, and some of the measures they took to prevent them from causing drug shortages.
How Biotech Firms Kept Raw Material Shortages From Affecting Patients During Pandemic
Biogen, Amgen, Lilly and Genentech experts shared tales of impending stockouts, particularly for single-use assemblies, filters and resins, and some of the measures they took to prevent them from causing drug shortages.
Achieving A Resilient Flu Vaccine Supply Chain Requires Retooling Most Of The Links
Expert panel draws lessons from COVID-19 in pressing for new manufacturing technologies, greater global coordination, more resilient supply chains and trained vaccine plant workers ready to “parachute” into the next outbreak.